<DOC>
	<DOCNO>NCT00431964</DOCNO>
	<brief_summary>This study examine safety , effect lung function , frequency symptom relate cystic fibrosis 24 week treatment antibiotic azithromycin 6-18 year-olds CF infect Pseudomonas aeruginosa .</brief_summary>
	<brief_title>Effect Azithromycin Lung Function 6-18 Year-olds With Cystic Fibrosis ( CF ) Not Infected With P. Aeruginosa</brief_title>
	<detailed_description>Azithromycin antibiotic show improve lung function patient cystic fibrosis ( CF ) whose lung infect bacterium call Pseudomonas aeruginosa . Scientists sure azithromycin work cystic fibrosis . It appear work kill bacteria Pseudomonas aeruginosa , may make bacteria bacteria less damaging lung reduce ability attach line lung , reduce bacteria 's ability make substance damage lung patient cystic fibrosis . Azithromycin may also work directly cell lung improve lung function . This could occur reduce inflammation ( swell ) lung , and/or make mucus less sticky , affect salt channel n't function correctly CF . If azithromycin work one way ; may also effective improve lung function cystic fibrosis patient infect Pseudomonas aeruginosa . We conduct research study examine safety , effect lung function frequency symptom relate cystic fibrosis 24 week treatment antibiotic azithromycin . This study design determine patient cystic fibrosis whose lung infect bacteria Pseudomonas aeruginosa benefit 24 week treatment antibiotic azithromycin . Benefit determine good pulmonary function test get sick less often compare placebo ( sugar pill ) . This study also design determine azithromycin safe administer 24 week cystic fibrosis patient infect Pseudomonas aeruginosa . By study , hope learn CF improve way treat . Comparison : Three time weekly azithromycin tablet add standard care , compare three time weekly placebo tablet add standard care .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Azithromycin</mesh_term>
	<criteria>Male female , 618 year age enrollment Confirmed diagnosis CF Written inform consent ( assent applicable ) Clinically stable enrollment assess site investigator FEV1 % predict &gt; 50 % Ability comply medication use , study visit , study procedure Ability swallow 250 mg tablet Weight le 18.0 kg Respiratory culture positive P. aeruginosa , NTM , B. cepacia complex within 1 year screening , AFB positive screening Allergy macrolide antibiotic Use macrolide antibiotic ( e.g. , azithromycin , clarithromycin ) within 60 day screen Use systemic corticosteroid intravenous oral antibiotic within 14 day screen Initiation high dose ibuprofen , Pulmozyme® , hypertonic saline aerosolize antibiotic within 30 day screen Chronic therapy drug know rare serious interaction azithromycin : amiodarone , digoxin , disopyramide , lovastatin , pimozide , rifabutin , nelfinavir Investigational drug use within 30 day screen Laboratory abnormality ( creatinine , liver function neutropenia ) screening confirm followup test prior randomization History biliary cirrhosis , portal hypertension , splenomegaly , splenomegaly physical exam History ventricular arrhythmia Other major organ dysfunction , exclude pancreatic dysfunction History lung transplantation currently lung transplant list Relative decrease FEV1 % predict ≥ 20 % screen enrollment visit Positive serum pregnancy test screening Pregnant , breastfeeding , postmenarche female , unwilling practice birth control participation study History alcohol , illicit drug medication abuse within 1 year screen judgment site investigator Presence condition abnormality opinion site investigator would compromise safety subject quality data</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>azithromycin , Zithromax</keyword>
</DOC>